Angiocrine Bioscience
Gayle Bresnahan is a Senior Director, Clinical Operations at Angiocrine Bioscience, Inc. Gayle has extensive experience in clinical operations and has held various roles at companies such as Travere Therapeutics, Intercept Pharmaceuticals, Halozyme Therapeutics, and Ambit Biosciences Corporation. Currently, Gayle is managing several Phase 3 global clinical trials in multiple countries. Prior to their current position, Gayle held roles at Dexcom, Gen Probe, Vical, and Quintiles.
Angiocrine Bioscience
Angiocrine Bioscience is a private, clinical-stage cell and gene therapy company harnessing the power of genetically modified human endothelial cells to regenerate tissues, restore function and rejuvenate patients with serious medical conditions.